Skip to content

Tailored Messaging for CRC Screening

Patient-directed Messaging to Increase Colorectal Cancer Screening

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03310892
Enrollment
600
Registered
2017-10-16
Start date
2017-10-09
Completion date
2023-10-01
Last updated
2023-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal cancer screening

Brief summary

This is a randomized controlled trial to to determine whether direct, tailored messaging to patients prior to scheduling colonoscopy will increase patient adherence to provider recommendation for screening colonoscopy.

Detailed description

The proposed study is a prospective, randomized trial. All eligible subjects (patients identified to be contacted to schedule screening colonoscopy) will be randomized to one of three study arms: usual scheduling process (control), a generic message arm, or a tailored message arm. Patients in the tailored message arm will receive a telephone call and be asked a series of questions that will be used to assign patients to one of four messaging cohorts. After these questions have been answered, the patient will then receive a tailored message corresponding to his or her respective messaging cohort, encouraging them to schedule a colonoscopy with a directed script. In the generic message arm, patients will receive a telephone call and be asked to answer the same series of questions as the tailored message group, then receive a single, standard script encouraging them to schedule a colonoscopy.

Interventions

BEHAVIORALGeneric message

Generic message

Tailored message

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. University of Pennsylvania Health System (UPHS) patients with an active order for screening or surveillance colonoscopy without an existing colonoscopy appointment 2. 50-75 years of age 3. Due for CRC screening or surveillance (defined as no evidence of: colonoscopy in the past 5 years, fecal immunochemical testing in the past 12 months, flexible sigmoidoscopy or CT colonography in the past 5 years, stool DNA test or Cologuard in the last 3 years)

Exclusion criteria

1. Age \<50 or \>75 2. Pregnant woman 3. Evidence of prior colonoscopy in the past 5 years, fecal immunochemical testing in the past 12 months, flexible sigmoidoscopy or CT colonography in the past 5 years, fecal DNA test or Cologuard in the last 3 years 4. History of colorectal cancer 5. History of inflammatory bowel disease (Crohn's disease or Ulcerative colitis) 6. History of colon surgery or resection 7. History of symptoms concerning for colorectal cancer, such as lower GI bleeding, within the past 6 months 8. Family history of a hereditary colorectal cancer syndrome, such as familial adenomatous polyposis (FAP) or hereditary non-polyposis colon cancer (HNPCC) 9. Current serious medical condition with estimated life expectancy of less than 6 months, such as incurable cancer, end-stage congestive heart failure, decompensated cirrhosis, end stage renal disease, etc. 10. Dementia 11. Does not speak English 12. No telephone number listed in electronic medical record 13. Has any other condition that, in the opinion of the investigator, excludes the patient from participating in this study

Design outcomes

Primary

MeasureTime frameDescription
Colonoscopy completion rate120 daysThe ratio of the number of participants who complete a colonoscopy to the total number of enrolled participants

Secondary

MeasureTime frameDescription
Colonoscopy scheduling rate120 daysThe ratio of the number of participants who schedule a colonoscopy to the total number of enrolled participants

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026